Finasteride Online

Buy Propecia, Finpecia, Proscar (Finasteride) to treat hair loss and BPH
Cheap qualitative Finasteride medication 1 mg and 5 mg tablets online



Lowest prices
Good quality
from $0.50 per pill
5% discount coupon: A1XKPKC


Low prices
High quality
from $0.54 per pill
5% discount coupon: A1XKPKC


Average prices
Best quality
from $0.83 per pill
5% discount coupon: 5OFF

For more offers please visit


Clinical Trials Experience

Proscar tablets are generally well tolerated; adverse reactions usually have been mild and transient.

4-Year Placebo-Controlled Study (PLESS)

In PLESS, 1524 patients treated with Finasteride (Proscar) and 1516 patients treated with placebo were evaluated for safety over a period of 4 years. The most frequently reported adverse reactions were related to sexual function. 3.7% (57 patients) treated with Finasteride (Proscar) 5 mg tablets and 2.1% (32 patients) treated with placebo discontinued therapy as a result of adverse reactions related to sexual function, which are the most frequently reported adverse reactions.

Here are the only clinical adverse reactions considered possibly, probably or definitely drug related by the investigator, for which the incidence on Proscar (Finasteride) was >= 1% and greater than placebo over the 4 years of the study. In years 2-4 of the study, there was no significant difference between treatment groups in the incidences of impotence, decreased libido and ejaculation disorder: impotence, decreased libido, decreased volume of ejaculate, ejaculation disorder, breast enlargement, breast tenderness, rash.

Phase III Studies and 5-Year Open Extensions

The adverse experience profile in the 1-year, placebo-controlled, Phase III studies, the 5-year open extensions, and PLESS were similar.

Medical Therapy of Prostatic Symptoms (MTOPS) Study

In the MTOPS study, 3047 men with symptomatic BPH were randomized to receive Proscar 5 mg/day (n=768), doxazosin 4 or 8 mg/day (n=756), the combination of Proscar 5 mg/day and doxazosin 4 or 8 mg/day (n=786), or placebo (n=737) for 4 to 6 years.

The incidence rates of drug-related adverse experiences reported by >= 2% of patients in any treatment group in the MTOPS Study are listed below.

The individual adverse effects which occurred more frequently in the combination group compared to either drug alone were: postural hypotension, asthenia, peripheral edema, decreased libido, dizziness, rhinitis, impotence and abnormal sexual function, abnormal ejaculation. Of these, the incidence of abnormal ejaculation in patients receiving combination therapy was comparable to the sum of the incidences of this adverse experience reported for the two monotherapies.

Combination therapy with finasteride and doxazosin was associated with no new clinical adverse experience.

Four patients in MTOPS reported the adverse experience breast cancer. Three of these patients were on finasteride only and one was on combination therapy.

The MTOPS Study was not specifically designed to make statistical comparisons between groups for reported adverse experiences. In addition, direct comparisons of safety data between the MTOPS study and previous studies of the single agents may not be appropriate based upon differences in patient population, dosage or dose regimen, and other procedural and study design elements.

Body as a whole: asthenia, headache

Cardiovascular: hypotension, postural hypotension

Metabolic and Nutritional: peripheral edema

Nervous: libido decreased, dizziness, somnolence

Respiratory: rhinitis, dyspnea

Urogenital: gynecomastia, abnormal ejaculation, impotence, sexual function abnormal

Long-Term Data

High-Grade Prostate Cancer

The PCPT trial was a 7-year randomized, double-blind, placebo-controlled trial that enrolled 18,882 men >= 55 years of age with a normal digital rectal examination and a PSA <= 3.0 ng/mL. Men received either Proscar (Finasteride 5 mg) or placebo daily. Patients were evaluated annually with PSA and digital rectal exams. Biopsies were performed for elevated PSA, an abnormal digital rectal exam, or the end of study. The incidence of Gleason score 8-10 prostate cancer was higher in men treated with finasteride (1.8%) than in those treated with placebo (1.1%). In a 4-year placebo-controlled clinical trial with another 5-alpha-reductase inhibitor (Avodart, Dutasteride), similar results for Gleason score 8-10 prostate cancer were observed (1% dutasteride vs 0.5% placebo).

No clinical benefit has been demonstrated in patients with prostate cancer treated with Finasteride (Proscar) tablets.

Breast Cancer

During the 4- to 6-year placebo- and comparator-controlled MTOPS study that enrolled 3047 men, there were 4 cases of breast cancer in men treated with finasteride but no cases in men not treated with finasteride. During the 4-year, placebo-controlled PLESS study that enrolled 3040 men, there were 2 cases of breast cancer in placebo-treated men but no cases in men treated with finasteride. During the 7 year placebo-controlled Prostate Cancer Prevention Trial (PCPT) that enrolled 18,882 men, there was 1 case of breast cancer in men treated with finasteride, and 1 case of breast cancer in men treated with placebo. The relationship between long-term use of finasteride and male breast neoplasia is currently unknown.

Sexual Function

There is no evidence of increased sexual adverse experiences with increased duration of treatment with Finasteride (Proscar). New reports of drug-related sexual adverse experiences decreased with duration of therapy.

Postmarketing Experience

The following additional adverse effects have been reported in post-marketing experience with Proscar (Finasteride) 5 mg tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

  • hypersensitivity reactions, including pruritus, urticaria, and swelling of the lips and face
  • testicular pain
  • male breast cancer

    Recent posts:

  • Buy Proscar (Finasteride) Online
  • Proscar prescribing information

    Copyright © 2016-2019, a division of pharmaceutical network.

    Home Page | Privacy Policy | Cookies Policy | Terms of Service | Contact Us